LianBio (LIANY)

Executive Summary

LianBio was a U.S.-based biopharmaceutical company that employed a 'search and develop' model to in-license and develop innovative therapies for the China and Asia-Pacific markets. Founded in 2020, the company aimed to bridge the access gap for novel medicines in these high-growth regions. However, in late 2023, LianBio announced a strategic wind-down to monetize its assets and return capital to shareholders. The company has since terminated all ongoing clinical trials, including Phase 2 studies of infigratinib in gastric cancer and Phase 1 studies of BBP-398 in solid tumors and NSCLC. Completed trials include Phase 3 studies of mavacamten for hypertrophic cardiomyopathy and lotilaner for blepharitis. As of early 2026, LianBio is in the process of liquidating its portfolio and distributing proceeds to investors. The company's market cap is approximately $13.3 million, reflecting its diminished operational status. Given the wind-down, future value creation hinges on the successful sale of remaining assets and efficient capital return, rather than pipeline advancement.

Upcoming Catalysts (preview)

• Q3 2026Sale of mavacamten Asia-Pacific rights70% success
• Q4 2026Final liquidation distribution announcement90% success
• Q3 2026Disposition of infigratinib or other pipeline assets50% success